by Matthew Johnson | Jan 4, 2017 | Federal Circuit Appeal, Real Party in Interest, Time Limits, Trial Institution
By Matt Johnson Today the Federal Circuit agreed to rehear en banc the panel decision in Wi-Fi One v. Broadcom Corp. on the issue of whether the PTAB’s findings regarding 35 U.S.C. § 315(b)’s one year bar can be reviewed on appeal. This question tests the...
by Jones Day's PTAB Team | Dec 21, 2016 | Pharmaceutical, Trial Institution
By Jeff Giering, Ph.D. and Cary Miller, Ph.D. On November 30, 2016, the PTAB issued decisions on the institution of inter partes reviews of U.S. Patent No. 6,667,061 (the ’061 patent), which relates to formulations for injectable suspensions having increased...
by Jones Day's PTAB Team | Dec 19, 2016 | Pharmaceutical, Trial Institution
By Wanli Tang, Ph.D. and J. Patrick Elsevier, Ph.D. On December 8, 2016, the PTAB issued six institution decisions in cases IPR2016-01127, IPR2016-01128, IPR2016-01129, IPR2016-01130, IPR2016-01131, and IPR2016-01132, agreeing to review claims of U.S. Patent Nos....
by David Cochran | Dec 16, 2016 | Prior Art Issues, Trial Institution
By Dave Cochran The PTAB denied institution of inter partes review in IPR2016-01083, Microsoft Corporation v. Corel Software, Inc., because the petitioner – Microsoft – failed to establish that a software reference manual that was part of its sole ground of...
by Joe Sauer | Nov 25, 2016 | Federal Circuit Appeal, Standing, Trial Institution
By Joe Sauer In a November 17, 2016 non-precedential decision, a Federal Circuit panel again considered whether its holding in Achates Reference Publishing, Inc. v. Apple Inc., 803 F.3d 652 (Fed. Cir. 2015) remains binding in view of the Supreme Court’s ruling in...
by Jones Day's PTAB Team | Nov 3, 2016 | Pharmaceutical, Trial Institution
By: Irina Britva and Patrick Elsevier On October 17, 2016, the PTAB declined the requests of Swiss Pharma International AG (“Swiss Pharma”) in cases IPR2016-00912, IPR2016-00915, and IPR2016-00916 to institute inter partes reviews (“IPRs”) of three patents owned by...
